Intellectual property | Science and Enterprise

A biotechnology company is developing treatments for cancer and other diseases using Crispr gene editing delivered… https://t.co/cZ13M2gPJk
about 20 hours ago
New post on Science and Enterprise: Biotech Creating More Efficient Crispr Therapies https://t.co/JAfb7hBMoH #Science #Business
about 20 hours ago
I have a Mode joke. It was a Moderna joke, but a messenger lost the RNA.
about 2 days ago
Behind the scenes, CEPI and BARDA were funding vaccine development and covering manufacturing costs. They helped ge… https://t.co/4F5vMbVsrK
about 3 days ago
A YouGov survey taken earlier this month indicates the U.S. public largely supports rejoining the Paris climate agr… https://t.co/eJd2v8G7K8
about 3 days ago

Stem Cell Respiratory Therapy Licensed in $1.4B Deal

By Alan, on November 20th, 2020%

Global drug maker Novartis is acquiring a stem cell-based treatment for a serious respiratory disease associated with Covid-19 infections. . . . → Read More: Stem Cell Respiratory Therapy Licensed in $1.4B Deal

Start-Up Gains Drug Nanoparticle Manufacturing Tech

By Alan, on November 13th, 2020%

A new enterprise spun-off from University of Connecticut is acquiring a technology for continuous manufacturing of nanoscale drug particles. . . . → Read More: Start-Up Gains Drug Nanoparticle Manufacturing Tech

Novartis Gains Synthetic Protein Therapies for Covid-19

By Alan, on October 28th, 2020%

Global drug maker Novartis is gaining access to two Covid-19 therapy candidates made from a library of synthetic protein components. . . . → Read More: Novartis Gains Synthetic Protein Therapies for Covid-19

Roche Gains Covid-19 Oral Drug Candidate

By Alan, on October 22nd, 2020%

Global drug maker Roche Group is acquiring an experimental antiviral therapy for Covid-19 infections taken as a oral drug, rather than an infusion. . . . → Read More: Roche Gains Covid-19 Oral Drug Candidate

Gene Therapy Delivery Tech Licensed in $1.8B Deal

By Alan, on October 14th, 2020%

A biotechnology company creating synthetic viruses with artificial intelligence to deliver gene therapies is licensing its technology to drug maker Roche. . . . → Read More: Gene Therapy Delivery Tech Licensed in $1.8B Deal

Start-Up Gains Access to Vaccine Nasal Spray Technology

By Alan, on October 12th, 2020%

A company developing techniques to deliver vaccines like Covid-19 with a nasal spray received an opportunity to license the process from University of Houston. . . . → Read More: Start-Up Gains Access to Vaccine Nasal Spray Technology

Start-Up Developing Thin Films for Vaccine Delivery

By Alan, on September 29th, 2020%

A new enterprise is creating thin films for vaccines, including Covid-19, to make possible their mass production and distribution at room temperatures. . . . → Read More: Start-Up Developing Thin Films for Vaccine Delivery

Start-Up Developing Microbial Cancer Detection Tests

By Alan, on August 13th, 2020%

A new company, spun off from university biomedical engineering labs, is creating early cancer diagnostics by analyzing microbial genetics in simple blood samples. . . . → Read More: Start-Up Developing Microbial Cancer Detection Tests

Breath Analysis Sensor Licensed to Detect Covid-19

By Alan, on August 10th, 2020%

Discoveries in a university lab that enable detection of Covid-19 infections from a person’s breath are being licensed for development by a biotechnology company. . . . → Read More: Breath Analysis Sensor Licensed to Detect Covid-19

Start-Up to Engineer T-Cells for Autoimmune Diseases

By Alan, on August 6th, 2020%

GentiBio Inc., a new enterprise in Boston, is starting work on creating engineered T-cells from the immune system to treat autoimmune diseases. . . . → Read More: Start-Up to Engineer T-Cells for Autoimmune Diseases

Science & Enterprise subscription

Specials

Follow us on Twitter

Guest Posts

Please share Science & Enterprise